Prophylactic infusions of high-dose respiratory syncytial virus (RSV) immune globulin (RSVIG) have been found to significantly reduce the incidence and severity of RSV infection according to a study directed by Jessie Groothuis, M.D., FAAP, of the University of Colorado School of Medicine and The Children's Hospital of Denver. RSV is the single most important respiratory pathogen in infancy and early childhood.

This content is only available via PDF.
You do not currently have access to this content.